You are here: Industry Insights > Phase 3

News List

Takeda's Ninlaro clears Phase 3 endpoint as maintenance therapy in multiple myeloma pharmafile
July 17, 2018
After making headlines with its mammoth deal to acquire Shire earlier this year, Takeda has emerged with new Phase 3 data for its oral proteasome inhibitor Ninlaro (ixazomib).
Roche's Tecentriq combo gives strong Phase 3 showing in triple negative breast cancer pharmafile
July 06, 2018
Roche has unveiled new Phase 3 data on its immunotherapy drug Tecentriq (atezolizumab) in combination with chemotherapy (Celgene’s Abraxane) as a first-line treatment
Revance Doses First Patient in ASPEN Phase 3 Clinical Program of RT002 Injectable for the Treatment of Cervical Dystonia americanpharmaceuticalreview
June 27, 2018
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions
Teva axes Phase 3 trial into chronic cluster headache pharmafile
June 22, 2018
With the advent of another week, there’s another trial discontinuation in the industry as Teva announces its decision to terminate further research into its calcitonin gene-related peptide (CGRP)
Anika's osteoarthritis pain drug falls short at Phase 3 pharmafile
June 22, 2018
Anika Therapeutics has become the latest in a recent string of firms to suffer a failure in a late-stage trial,
Avenue Announces Positive Phase 3 Trial Results contractpharma
May 22, 2018
Avenue Therapeutics announced that its first pivotal Phase 3 trial of IV tramadol achieved the primary endpoint of a statistically significant improvement
Bristol-Myers Squibb drops phase 3 trials of $800M IDO drug fiercebiotech
May 02, 2018
Bristol-Myers Squibb has pulled two phase 3 clinical trials of the IDO1 inhibitor it acquired through an $800 million takeover of Flexus.